Epigenetic research in cancer epidemiology: Trends, opportunities, and challenges

Cancer Epidemiology Biomarkers and Prevention

Volumn 23, Issue 2, 2014, Pages 223-233

  Verma, Mukesh ^a   Rogers, Scott ^a   Divi, Rao L ^a   Schully, Sheri D ^a   Nelson, Stefanie ^a   Su, L Joseph ^a   Ross, Sharon A ^a   Pilch, Susan ^b   Winn, Deborah M ^a   Khoury, Muin J ^a,c  

^a NATIONAL CANCER INSTITUTE   (United States)

^b Information Services and Research   (United States)

^c NATIONAL CENTER ON BIRTH DEFECTS AND DEVELOPMENTAL DISABILITIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA METHYLTRANSFERASE; MICRORNA;

BLADDER CANCER; BLOOD CELL; BRAIN CANCER; BREAST CANCER; CANCER EPIDEMIOLOGY; CANCER RESEARCH; CANCER TISSUE; CASE CONTROL STUDY; CHEEK; CHROMATIN IMMUNOPRECIPITATION; COLORECTAL CANCER; DNA METHYLATION; EPIGENETICS; ESOPHAGUS CANCER; GENE EXPRESSION PROFILING; HEAD AND NECK CANCER; HISTONE MODIFICATION; HUMAN; LIVER CANCER; LUNG CANCER; NATIONAL HEALTH ORGANIZATION; OVARY CANCER; PANCREAS CANCER; PRIORITY JOURNAL; PROSPECTIVE STUDY; REVIEW; SPUTUM; STOMACH CANCER; EPIDEMIOLOGY; GENETICS; MOLECULAR EPIDEMIOLOGY; NEOPLASMS; PROCEDURES; TRENDS;

EPIDEMIOLOGIC STUDIES; EPIGENOMICS; HUMANS; MOLECULAR EPIDEMIOLOGY; NEOPLASMS;

EID: 84893674846     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-13-0573     Document Type: Review

References (89)

1. Baylin SB, Jones PA. A decade of exploring the cancer epigenome -biological and translational implications. Nat Rev Cancer 2011;11: 726-34.
2. Jones P. Out of Africa and into epigenetics: discovering reprogramming drugs. Nat Cell Biol 2011;13:2.
3. Feinberg AP. Genome-scale approaches to the epigenetics of common human disease. Virchows Archiv 2010;456:13-21.
4. Khare S, Verma M. Epigenetics of colon cancer. Methods Mol Biol 2012;863:177-85.
5. Kumar D, Verma M. Methods in cancer epigenetics and epidemiology. Methods Mol Biol (Clifton, NJ) 2009;471:273-88.
6. Verma M, Maruvada P, Srivastava S. Epigenetics and cancer. Crit Rev Clin Lab Sci 2004;41:585-607.
7. Verma M, Dunn BK, Ross S, Jain P, Wang W, Hayes R, et al. Early detection and risk assessment: proceedings and recommendations from theWorkshop on Epigenetics in Cancer Prevention. AnnNYAcad Sci 2003;983:298-319.
8. Dunn BK, Verma M, Umar A. Epigenetics in cancer prevention: early detection and risk assessment: introduction. Ann N Y Acad Sci 2003; 983:1-4.
9. Verma M, Srivastava S. Epigenetics in cancer: implications for early detection and prevention. Lancet Oncol 2002;3:755-63.
10. Feinberg AP. Epigenetics at the epicenter of modern medicine. JAMA 2008;299:1345-50.
11. Iwagami S, Baba Y, Watanabe M, Shigaki H, Miyake K, Ishimoto T, et al. LINE-1 hypomethylation is associated with a poor prognosis among patients with curatively resected esophageal squamous cell carcinoma. Ann Surg 2013;257:449-55.
12. Bradly DP, Gattuso P, Pool M, Basu S, Liptay M, Bonomi P, et al. CDKN2A (p16) promoter hypermethylation influences the outcome in young lung cancer patients. Diagn Mol Pathol 2012;21: 207-13.
13. Brasset E, Chambeyron S. Epigenetics and transgenerational inheritance. Genome Biol 2013;14:306.
14. Wild CP, Scalbert A, Herceg Z. Measuring the exposome: a powerful basis for evaluating environmental exposures and cancer risk. Environ Mol Mutagen 2013;54:480-99.
15. Hou L, Zhang X, Wang D, Baccarelli A. Environmental chemical exposures and human epigenetics. Int J Epidemiol 2012;41:79-105.
16. Costa FF. Epigenomics in cancer management. Cancer Manag Res 2010;2:255-65.
17. Verma M. Cancer control and prevention: nutrition and epigenetics. Curr Opin Clin Nutr Metab Care 2013;16:376-84.
18. Mill J, Heijmans BT. From promises to practical strategies in epigenetic epidemiology. Nat Rev Genet 2013;14:585-94.
19. Terry MB, Delgado-Cruzata L, Vin-Raviv N, Wu HC, Santella RM. DNA methylation in white blood cells: association with risk factors in epidemiologic studies. Epigenetics 2011;6:828-37.
20. Huang WY, Su LJ, Hayes RB, Moore LE, Katki HA, Berndt SI, et al. Prospective study of genomic hypomethylation of leukocyte DNA and colorectal cancer risk. Cancer Epidemiol Biomarkers Prev 2012;21: 2014-21.
21. Delgado-Cruzata L, Wu HC, Perrin M, Liao Y, Kappil MA, Ferris JS, et al. Global DNA methylation levels in white blood cell DNA from sisters discordant for breast cancer from the New York site of the Breast Cancer Family Registry. Epigenetics 2012;7:868-74.
22. Eads CA, Danenberg KD, Kawakami K, Saltz LB, Blake C, Shibata D, et al. Methy Light: a high-throughput assay to measure DNA methylation. Nucleic Acids Res 2000;28:E32.
23. Ulrich CM, Toriola AT, Koepl LM, Sandifer T, Poole EM, Duggan C, et al. Metabolic, hormonal and immunological associations with global DNA methylation among postmenopausal women. Epigenetics 2012;7: 1020-8.
24. Gao Y, Baccarelli A, Shu XO, Ji BT, Yu K, Tarantini L, et al. Blood leukocyte Alu and LINE-1 methylation and gastric cancer risk in the Shanghai Women's Health Study. Br J Cancer 2012;106: 585-91.
25. Wu HC, Delgado-Cruzata L, Flom JD, Perrin M, Liao Y, Ferris JS, et al. Repetitive element DNA methylation levels in white blood cell DNA from sisters discordant for breast cancer from the New York site of the Breast Cancer Family Registry. Carcinogenesis 2012; 33:1946-52.
26. Mirabello L, Schiffman M, Ghosh A, Rodriguez AC, Vasiljevic N, Wentzensen N, et al. Elevated methylation ofHPV16DNAis associated with the development of high grade cervical intraepithelial neoplasia. Int J Cancer 2013;132:1412-22.
27. Wentzensen N, Sun C, Ghosh A, Kinney W, Mirabello L, Wacholder S, et al. Methylation of HPV18, HPV31, and HPV45 genomes and cervical intraepithelial neoplasia grade 3. J Natl Cancer Inst 2012;104:1738-49.
28. Mirabello L, Kratz CP, Savage SA, Greene MH. Promoter methylation of candidate genes associated with familial testicular cancer. Int J Mol Epidemiol Genet 2012;3:213-27.
29. Wong EM, Southey MC, Fox SB, Brown MA, Dowty JG, Jenkins MA, et al. Constitutional methylation of the BRCA1 promoter is specifically associated with BRCA1 mutation-Associated pathology in early-onset breast cancer. Cancer Prev Res (Phila) 2011;4:23-33.
30. Qian B, Katsaros D, Lu L, Canuto EM, Benedetto C, Beeghly-Fadiel A, et al. IGF-II promoter specific methylation and expression in epithelial ovarian cancer and their associations with disease characteristics. Oncol Rep 2011;25:203-13.
31. Li WQ, Pan KF, Zhang Y, Dong CX, Zhang L, Ma JL, et al. RUNX3 methylation and expression associated with advanced precancerous gastric lesions in a Chinese population. Carcinogenesis 2011;32: 406-10.
32. Rizvi MM, Alam MS, Ali A, Mehdi SJ, Batra S, Mandal AK. Aberrant promoter methylation and inactivation of PTEN gene in cervical carcinoma from Indian population. J Cancer Res Clin Oncol 2011; 137:1255-62.
33. Levine AJ, Win AK, Buchanan DD, Jenkins MA, Baron JA, Young JP, et al. Cancer risks for the relatives of colorectal cancer cases with a methylated MLH1 promoter region: data from the Colorectal Cancer Family Registry. Cancer Prev Res (Phila) 2012;5:328-35.
34. Sturgeon SR, Balasubramanian R, Schairer C, Muss HB, Ziegler RG, Arcaro KF. Detection of promoter methylation of tumor suppressor genes in serum DNA of breast cancer cases and benign breast disease controls. Epigenetics 2012;7:1258-67.
35. Budinska E, Popovici V, Tejpar S, D'Ario G, Lapique N, Sikora KO, et al. Gene expression patterns unveil a new level of molecular heterogeneity in colorectal cancer. J Pathol 2013; 231:63-76.
36. Hughes LA, Melotte V, de Schrijver J, de Maat M, Smit VT, Bovee JV, et al. The CpG island methylator phenotype: what's in a name? Cancer Res 2013;73:5858-68.
37. Nishihara R,Morikawa T, Kuchiba A, Lochhead P, Yamauchi M, Liao X, et al. A prospective study of duration of smoking cessation and colorectal cancer risk by epigenetics-related tumor classification. Am J Epidemiol 2013;178:84-100.
38. Hughes LA, Simons CC, van den Brandt PA, Goldbohm RA, de Goeij AF, de Bruine AP, et al. Body size, physical activity and risk of colorectal cancer with or without the CpGisland methylator phenotype (CIMP). PloS ONE 2011;6:e18571.
39. Schernhammer ES, Giovannucci E, Baba Y, Fuchs CS, Ogino S. B vitamins, methionine and alcohol intake and risk of colon cancer in relation to BRAF mutation and CpG island methylator phenotype (CIMP). PloS ONE 2011;6:e21102.
40. Razzak AA, Oxentenko AS, Vierkant RA, Tillmans LS, Wang AH, Weisenberger DJ, et al. Alcohol intake and colorectal cancer risk by molecularly defined subtypes in a prospective study of older women. Cancer Prev Res (Phila) 2011;4:2035-43.
41. Lao VV, Grady WM. Epigenetics and colorectal cancer. Nat Rev Gastroenterol Hepatol 2011;8:686-700.
42. Relton CL, Davey Smith G. Is epidemiology ready for epigenetics? Int J Epidemiol 2012;41:5-9.
43. Cash HL, Tao L, Yuan JM, Marsit CJ, Houseman EA, Xiang YB, et al. LINE-1 hypomethylation is associated with bladder cancer risk among nonsmoking Chinese. Int J Cancer 2012;130:1151-9.
44. Alshatwi AA. Breast cancer risk, dietary intake, and methylenetetrahydrofolate reductase (MTHFR)single nucleotide polymorphisms. Food Chem Toxicol 2010;48:1881-5.
45. Cebrian A, Pharoah PD, Ahmed S, Ropero S, Fraga MF, Smith PL, et al. Genetic variants in epigenetic genes and breast cancer risk. Carcinogenesis 2006;27:1661-9.
46. Chung MT, Sytwu HK, Yan MD, Shih YL, Chang CC, Yu MH, et al. Promoter methylation of SFRPs gene family in cervical cancer. Gynecol Oncol 2009;112:301-6.
47. Kaaks R, Stattin P, Villar S, Poetsch AR, Dossus L, Nieters A, et al. Insulin-like growth factor-II methylation status in lymphocyte DNA and colon cancer risk in the Northern Sweden Health and Disease cohort. Cancer Res 2009;69:5400-5.
48. Zhang C, Wang C, Chen X, Yang C, Li K, Wang J, et al. Expression profile of microRNAs in serum: a fingerprint for esophageal squamous cell carcinoma. Clin Chem 2010;56:1871-9.
49. Liu R, Zhang C, Hu Z, Li G, Wang C, Yang C, et al. A five-microRNA signature identified from genome-wide serum microRNA expression profiling serves as a fingerprint for gastric cancer diagnosis. Eur J Cancer (Oxford, England : 1990) 2011;47:784-91.
50. Hsiung DT, Marsit CJ, Houseman EA, Eddy K, Furniss CS, McClean MD, et al. Global DNA methylation level in whole blood as a biomarker in head and neck squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev 2007;16:108-14.
51. Claus R, Hackanson B, Poetsch AR, Zucknick M, Sonnet M, Blagitko-Dorfs N, et al. Quantitative analyses of DAPK1 methylation in AML and MDS. Int J Cancer 2012;131:E138-42.
52. Akkiz H, Bayram S, Bekar A, Akgollu E, Ulger Y. A functional polymorphism in pre-microRNA-196a-2 contributes to the susceptibility of hepatocellular carcinoma in a Turkish population: a case-control study. J Viral Hepat 2011;18:e399-407.
53. Zhou J, Yu L, Gao X, Hu J, Wang J, Dai Z, et al. Plasma microRNA panel to diagnose hepatitis B virus-related hepatocellular carcinoma. J Clin Oncol 2011;29:4781-8.
54. Cao Y, Miao XP, Huang MY, Deng L, Liang XM, Lin DX, et al. Polymorphisms of methylenetetrahydrofolate reductase are associated with a high risk of nasopharyngeal carcinoma in a smoking population from Southern China. Mol Carcinog 2010;49:928-34.
55. Bastian PJ, Palapattu GS, Yegnasubramanian S, Rogers CG, Lin X, Mangold LA, et al. CpG island hypermethylation profile in the serum of men with clinically localized and hormone refractory metastatic prostate cancer. J Urol 2008;179:529-34.
56. Liao LM, Brennan P, van Bemmel DM, Zaridze D, Matveev V, Janout V, et al. LINE-1 methylation levels in leukocyte DNA and risk of renal cell cancer. PloS ONE 2011;6:e27361.
57. Matsubayashi H, Sato N, Brune K, Blackford AL, Hruban RH, Canto M, et al. Age-And disease-related methylation of multiple genes in nonneoplastic duodenum and in duodenal juice. Clin Cancer Res 2005;11:573-83.
58. Franzmann EJ, Reategui EP, Pedroso F, Pernas FG, Karakullukcu BM, Carraway KL, et al. Soluble CD44 is a potential marker for the early detection of head and neck cancer. Cancer Epidemiol Biomarkers Prev 2007;16:1348-55.
59. Seligson DB, Horvath S, McBrian MA, Mah V, Yu H, Tze S, et al. Global levels of histone modifications predict prognosis in different cancers. Am J Pathol 2009;174:1619-28.
60. Weiss G, Cottrell S, Distler J, Schatz P, Kristiansen G, Ittmann M, et al. DNA methylation of the PITX2 gene promoter region is a strong independent prognostic marker of biochemical recurrence in patients with prostate cancer after radical prostatectomy. J Urol 2009;181: 1678-85.
61. Curtin K, SamowitzWS, Ulrich CM, Wolff RK, Herrick JS, Caan BJ, et al. Nutrients in folate-mediated, one-carbon metabolism and the risk of rectal tumors in men and women. Nutr Cancer 2011;63:357-66.
62. Matsubayashi H, Canto M, Sato N, Klein A, Abe T, Yamashita K, et al. DNA methylation alterations in the pancreatic juice of patients with suspected pancreatic disease. Cancer Res 2006;66:1208-17.
63. Sun W, Zaboli D, Wang H, Liu Y, Arnaoutakis D, Khan T, et al. Detection of TIMP3 promoter hypermethylation in salivary rinse as an independent predictor of local recurrence-free survival in head and neck cancer. Clin Cancer Res 2012;18:1082-91.
64. Tessema M, Belinsky SA. Mining the epigenome for methylated genes in lung cancer. Proc Am Thorac Soc 2008;5:806-10.
65. Baryshnikova E, Destro A, Infante MV, Cavuto S, Cariboni U, Alloisio M, et al. Molecular alterations in spontaneous sputum of cancer-free heavy smokers: results from a large screening program. Clin Cancer Res 2008;14:1913-9.
66. Dudziec E, Miah S, Choudhry HM, Owen HC, Blizard S, Glover M, et al. Hypermethylation of CpG islands and shores around specific micro-RNAs and mirtrons is associated with the phenotype and presence of bladder cancer. Clin Cancer Res 2011;17:1287-96.
67. Mueller WC, Spector Y, Edmonston TB, St Cyr B, Jaeger D, Lass U, et al. Accurate classification of metastatic brain tumors using a novel microRNA-based test. Oncologist 2011;16:165-74.
68. Dietrich D, Krispin M, Dietrich J, Fassbender A, Lewin J, Harbeck N, et al. CDO1 promoter methylation is a biomarker for outcome prediction of anthracycline treated, estrogen receptor-positive, lymph nodepositive breast cancer patients. BMC Cancer 2010;10:247.
69. Rawson JB, Mrkonjic M, Daftary D, Dicks E, Buchanan DD, Younghusband HB, et al. Promoter methylation of Wnt5a is associated with microsatellite instability and BRAF V600E mutation in two large populations of colorectal cancer patients. Br J Cancer 2011;104:1906-12.
70. Worthley DL, Whitehall VL, Buttenshaw RL, Irahara N, Greco SA, Ramsnes I, et al. DNAmethylation within the normal colorectal mucosa is associated with pathway-specific predisposition to cancer. Oncogene 2010;29:1653-62.
71. Jin Z, Cheng Y, Gu W, Zheng Y, Sato F, Mori Y, et al. A multicenter, double-blinded validation study of methylation biomarkers for progression prediction in Barrett's esophagus. Cancer Res 2009;69: 4112-5.
72. Chang MS, Uozaki H, Chong JM, Ushiku T, Sakuma K, Ishikawa S, et al. CpG island methylation status in gastric carcinoma with and without infection of Epstein-Barr virus. Clin Cancer Res 2006;12: 2995-3002.
73. Delfino KR, Serao NV, Southey BR, Rodriguez-Zas SL. Therapy-, gender-And race-specific microRNA markers, target genes and networks related to glioblastoma recurrence and survival. Cancer Genomics Proteomics 2011;8:173-83.
74. Avissar M, McClean MD, Kelsey KT, Marsit CJ. MicroRNA expression in head and neck cancer associates with alcohol consumption and survival. Carcinogenesis 2009;30:2059-63.
75. Dikshit RP, Gillio-Tos A, Brennan P, De Marco L, Fiano V, Martinez-Penuela JM, et al. Hypermethylation, risk factors, clinical characteristics, and survival in 235 patients with laryngeal and hypopharyngeal cancers. Cancer 2007;110:1745-51.
76. Ji J, Shi J, Budhu A, Yu Z, Forgues M, Roessler S, et al. MicroRNA expression, survival, and response to interferon in liver cancer.NEngl J Med 2009;361:1437-47.
77. Limsui D, Vierkant RA, Tillmans LS, Wang AH, Weisenberger DJ, Laird PW, et al. Cigarette smoking and colorectal cancer risk by molecularly defined subtypes. J Natl Cancer Inst 2010;102:1012-22.
78. Brock MV, Hooker CM, Ota-Machida E, Han Y, Guo M, Ames S, et al. DNAmethylation markers and early recurrence in stage I lung cancer.N Engl J Med 2008;358:1118-28.
79. Bray I, Bryan K, Prenter S, Buckley PG, Foley NH, Murphy DM, et al. Widespread dysregulation of MiRNAs by MYCN amplification and chromosomal imbalances in neuroblastoma: association of miRNA expression with survival. PloS ONE 2009;4:e7850.
80. Cao J, Zhou J, Gao Y, Gu L, Meng H, Liu H, et al. Methylation of p16 CpG island associated with malignant progression of oral epithelial dysplasia: a prospective cohort study. Clin Cancer Res 2009;15: 5178-83.
81. An J, Wei Q, Liu Z, Lu KH, Cheng X, Mills GB, et al. Messenger RNA expression and methylation of candidate tumor-suppressor genes and risk of ovarian cancer-A case-control analysis. Int J Mol Epidemiol Genet 2010;1:1-10.
82. Dai W, Teodoridis JM, Zeller C, Graham J, Hersey J, Flanagan JM, et al. Systematic CpG islands methylation profiling of genes in the wnt pathway in epithelial ovarian cancer identifies biomarkers of progression-free survival. Clin Cancer Res 2011;17:4052-62.
83. Donahue TR, Tran LM, Hill R, Li Y, Kovochich A, Calvopina JH, et al. Integrative survival-based molecular profiling of human pancreatic cancer. Clin Cancer Res 2012;18:1352-63.
84. Kim SJ, Kelly WK, Fu A, Haines K, Hoffman A, Zheng T, et al. Genomewidemethylation analysis identifies involvement ofTNF-Alphamediated cancer pathways in prostate cancer. Cancer Lett 2011;302:47-53.
85. Slattery ML, Curtin K, Wolff RK, Herrick JS, Caan BJ, Samowitz W. Diet, physical activity, and body size associations with rectal tumor mutations and epigenetic changes. Cancer Causes Control 2010;21: 1237-45.
86. Nickerson ML, Jaeger E, Shi Y, Durocher JA, Mahurkar S, Zaridze D, et al. Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors. Clin Cancer Res 2008;14:4726-34.
87. Costa VL, Henrique R, Danielsen SA, Duarte-Pereira S, Eknaes M, Skotheim RI, et al. Three epigenetic biomarkers, GDF15, TMEFF2, and VIM, accurately predict bladder cancer from DNA-based analyses of urine samples. Clin Cancer Res 2010;16:5842-51.
88. Baden J, Green G, Painter J, Curtin K, Markiewicz J, Jones J, et al. Multicenter evaluation of an investigational prostate cancer methylation assay. J Urol 2009;182:1186-93.
89. Vener T, Derecho C, Baden J, Wang H, Rajpurohit Y, Skelton J, et al. Development of a multiplexed urine assay for prostate cancer diagnosis. Clin Chem 2008;54:874-82.